2008 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
February 28, 2008
InNexus Biotechnology Develops Diagnostics Business Based on DXL™ Technology
- Patent applications recently filed protecting development of diagnostics and research tools to be offered to the pharmaceutical and diagnostics industry.
BRITISH COLUMBIA, Canada-28 February 2008-InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™),today announced it has filed certain patent applications for the development of diagnostic and research tools based on its DXL™ technology platform. The new commercial offering, DXLdiagnostics™, will be further prepared over the next year and commercialized as a quantitative amplification technology aimed at improving and speeding up the development of antibody-based diagnostic tests offered to the pharmaceutical and diagnostics industry and contract research organizations.
InNexus Chairman and CEO, Jeff Morhet said, “To develop a diagnostics offering is an exciting situation evolved from the work we have conducted in the last year during the development of InNexus’ pipeline of preclinical candidates. It clearly demonstrates an expanded development and market potential of DXL™ technology. Earlier, faster and more accurate diagnosis is driving the entire life science marketplace, which is something we can’t ignore. We expect to have the commercial offering ready during early next year and the immediate application of DXL™ technology to improve a whole host of antibody-based diagnostics along with our development work has moved us to recently file significant and broad patent protection for the DXLdiagnostics™ platform”.
Dr. Thomas Kindt, InNexus’ Chief Scientific Officer said, “The signature property of DXL™ antibodies i.e., their ability to form multimers subsequent to binding to their target antigen, has potential to greatly enhance their value in diagnostic as well as in therapeutic applications. In the simplest case, a DXL™ antibody used to detect a target antigen will yield a several-fold stronger signal upon binding a fixed amount of the antigen because more antibodies will accumulate at the target based on the autophilic (self-binding) nature of the DXL™ antibodies.”
Accumulating data from in vitro and in vivo studies suggest that DXL™ antibodies are superior to comparative antibodies in killing tumor cells, prompting their use as agents to treat cancer. The same property giving enhanced potency in killing tumor cells has and will be exploited to give detection of lower levels of targeted antigens by increasing the amount of antibody at the antigen site. There are few limitations to the type of assay to which the DXL™ antibodies can be expected to give superior results. Preliminary results show significantly enhanced signals with antigens on cell surfaces as well as those coupled to a number of artificial supports.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet, Chairman & Chief Executive Officer
Dr. Thomas Kindt, Chief Scientific Officer
InNexus Biotechnology Inc.
480-862-7500
www.ixsbio.com
